Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in Non-active Progressive Multiple Sclerosis
NCT06675864Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2024
- Primary completion
- Jun 2030
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 7
01
Overview
A Phase 2 trial of rapcabtagene autoleucel in multiple sclerosis (MS), sponsored by Novartis. Started Dec 2024; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06675864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675864.